Medinno (Drug Discovery) Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $29.8M

  • Investors
  • 8

Medinno (Drug Discovery) General Information

Description

Developer of small-molecule therapeutics designed to address unmet treatment needs in chronic wounds, dermatological, and ophthalmic diseases. The company offers locally administered multi-target drug candidates engineered to act at affected tissues while limiting systemic exposure, enabling patients with inflammatory, autoimmune, and chronic wound conditions to access targeted treatments with improved safety profiles.

Contact Information

Formerly Known As
Henan Lianglu Pharmaceutical Technology, MyInno Medical Technology (Zhuhai)
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 35, 3rd Floor, Building 9
  • Number 129 Dingxing Road, Tangjiawan Town, High-tech Zone
  • Zhuhai, Guangdong 519000
  • China
+86 150
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Unit 35, 3rd Floor, Building 9
  • Number 129 Dingxing Road, Tangjiawan Town, High-tech Zone
  • Zhuhai, Guangdong 519000
  • China
+86 150

Medinno (Drug Discovery) Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medinno (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 16-Sep-2026 $29.8M Completed Generating Revenue
1. Later Stage VC 15-Jan-2024 Completed Generating Revenue
To view Medinno (Drug Discovery)’s complete valuation and funding history, request access »

Medinno (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medinno (Drug Discovery) Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Insight Capital (Taicang) Venture Capital Minority
Laurel Venture Capital Venture Capital Minority
Sunshine Ronghui Capital Investment Management Corporate Venture Capital Minority
Xiamen C&D Corporation Corporation Minority
Xiamen Hi-Tech Innovation Center Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Medinno (Drug Discovery) FAQs

  • When was Medinno (Drug Discovery) founded?

    Medinno (Drug Discovery) was founded in 2017.

  • Where is Medinno (Drug Discovery) headquartered?

    Medinno (Drug Discovery) is headquartered in Zhuhai, China.

  • What is the size of Medinno (Drug Discovery)?

    Medinno (Drug Discovery) has 8 total employees.

  • What industry is Medinno (Drug Discovery) in?

    Medinno (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Medinno (Drug Discovery) a private or public company?

    Medinno (Drug Discovery) is a Private company.

  • What is Medinno (Drug Discovery)’s current revenue?

    The current revenue for Medinno (Drug Discovery) is .

  • How much funding has Medinno (Drug Discovery) raised over time?

    Medinno (Drug Discovery) has raised $29.8M.

  • Who are Medinno (Drug Discovery)’s investors?

    Insight Capital (Taicang), Laurel Venture Capital, Sunshine Ronghui Capital Investment Management, Xiamen C&D Corporation, and Xiamen Hi-Tech Innovation Center are 5 of 8 investors who have invested in Medinno (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process